the Role of plin5 in the Development of a Sequence Polymorphism in Patatin-like Phospholipid Domain Containing Protein 3 Polymorphism-associated Nonalcoholic Fatty Liver Disease
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 240
- Locations
- 1
- Primary Endpoint
- The severity of non-alcoholic fatty liver disease
Study Overview
Brief Summary
To further clarify the role of sequence polymorphism in patatin-like phospholipid domain containing protein 3 in the development of nonalcoholic fatty liver disease.
Detailed Description
A sequence polymorphism in patatin-like phospholipid domain containing protein 3 is significantly associated with nonalcoholic fatty liver disease, but its mechanism underlying this association remains obscure. We introduce the human samples of liver to clarify the relationship between the expression of plin5 and the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease, analyze the lipid metabolism and lipotoxicity of hepatocytes to elucidate the mechanisms of plin5 in the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease. Our study will contribute to the mechanism of nonalcoholic fatty liver disease, and its prevention and therapy.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
The severity of non-alcoholic fatty liver disease
Time Frame: 3 months
Evaluating by ultrasound the severity of non-alcoholic fatty liver disease
Secondary Outcomes
- The expression of plin5(3 months)